Healio coverage available at: Tsibadze N, Tskhakaia I, Tan I
Tracking metrics like A1C, weight, lipid panels, and renal function ensures optimal outcomes
Researchers in these situations should discontinue use and consult with healthcare providers
Because the GLP-1 weight loss industry is constantly changing, please reach out to Ro to check current availability in your state
Operationally, GLP-1 therapies have also increased the administrative burden
Gastrointestinal symptomsparticularly nausea, vomiting, diarrhoea, and constipationare the most frequently reported adverse effects of GLP-1 receptor agonists, occurring in 2050% of patients depending on the specific agent and dose according to clinical trials and SmPC data